# A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body

> **NCT01529684** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 5 (actual)

## Conditions studied

- Advanced Solid Tumors
- Pharmacokinetics of 14C-OSI-906

## Interventions

- **DRUG:** radio-labeled OSI-906
- **DRUG:** OSI-906

## Key facts

- **NCT ID:** NCT01529684
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-19
- **Primary completion:** 2012-12-08
- **Final completion:** 2013-02-20
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01529684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01529684, "A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01529684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*